Korro to Participate in Upcoming Investor Conferences
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
馬薩諸塞州劍橋市，2024年11月21日（環球新聞）-- Korro Bio, Inc.（Korro）（納斯達克：KRRO）是一家臨床階段生物製藥公司，專注於開發一種基於RNA編輯的新型基因藥物，旨在治療稀有和高發疾病，今天宣佈管理層成員將參加以下投資者會議：
Piper Sandler 36th Annual Healthcare Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conference.
派傑投資第36屆醫療保健年會
首席執行官兼總裁Ram Aiyar博士將於2024年12月3日星期二，下午4:00（東部時間）參與一個爐邊談話。首席財務官Vineet Agarwal和首席醫療官Kemi Olugemo萬博士，FAAN，也將在會議上參加1對1的投資者會議。
7th Annual Evercore ISI HealthCONx Conference
Dr. Aiyar will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30 a.m. ET. Mr. Agarwal and Dr. Olugemo will also be participating at the conference.
第7屆Evercore ISI HealthCONx會議
Aiyar博士將於2024年12月4日星期三，上午7:30（東部時間）參與一個爐邊談話。Agarwal先生和Olugemo博士也將參加會議。
Citi's 2024 Global Healthcare Conference
Dr. Aiyar, Mr. Agarwal, and Dr. Olugemo will participate in 1x1 investor meetings on Thursday, December 5, 2024.
花旗銀行2024年全球醫療保健會議
Aiyar博士、Agarwal先生和Olugemo博士將於2024年12月5日（星期四）參加一對一的投資者會議。
Oppenheimer Movers in Rare Disease Summit
Dr. Aiyar will participate in a panel titled "Recent Progress on RNA Editing" on Thursday, December 12, 2024, at 3:40 p.m. ET. Mr. Agarwal will also be participating at the conference.
Oppenheimer在罕見疾病峯會中的 Movers
Aiyar博士將於2024年12月12日（星期四）下午3:40（東部時間）參與一個名爲「RNA編輯的最新進展」的小組討論。Agarwal先生也將參與此次會議。
The live webcasts of the Piper Sandler and Evercore fireside chats can be accessed on the "Events & Presentations" page in the Investor section of Korro's website at . Following the presentations, a replay of the event will be available for 30 days.
派傑投資和evercore的爐邊聊天的現場直播可以在Korro網站投資者部分的「活動與演示」頁面訪問。演示結束後，活動的重播將在30天內提供。
About Korro
關於Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro是一家臨床階段的生物製藥公司，專注於開發一種新型基因藥物，用於治療罕見和高發疾病，採用其專有的RNA編輯平台。Korro正在生成一系列差異化的項目，旨在利用身體的自然RNA編輯過程，影響精準而短暫的單鹼基編輯。通過編輯RNA而不是DNA，Korro正在擴大基因藥物的應用範圍，提供額外的精確度和可調性，這可能會提高特異性和長期耐受性。利用基於寡核苷酸的方法，Korro預計將通過利用其專有平台與前所未有的遞送方式、製造專業知識以及已建立的已批准寡核苷酸藥物的監管途徑，將其藥物帶給患者。Korro總部位於馬薩諸塞州的劍橋市。如需更多信息，請訪問korrobio.com。
Korro Contact Information
Korro聯繫信息：IR@korrobio.com
Investor & Media Contact
Tim Palmer
IR@korrobio.com
投資者和媒體聯繫人
Tim Palmer
Glenn.silver@finnpartners.com
